Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Matthew Zirwas MD

Matthew J. Zirwas MD

Director, Contact Dermatitis Center, Ohio State University, Gahanna, Ohio

Dr. Zirwas is the Director of the Contact Dermatitis Center at The Ohio State University, where he is also the residency program director for dermatology.

Disclosures

Dr. Zirwas is a speaker and consultant for Pfizer, Abbvie, Sanofi, Regeneron, Leo, Galderma and Incyte.

Recent Contributions to PracticeUpdate:

  1. Association of Gabapentinoid Use With Risk of Hip Fracture
  2. Efficacy of Dupilumab for Chronic Hand Eczema
  3. Assessing the Impact of Prior Authorizations on Dermatology Residents
  4. New Understanding of the Environmental Causes of Atopic Dermatitis
  5. Real-World Evidence on the Use of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
  6. Analysis of Contact Allergens in Single-Use Polyvinyl Chloride Medical Examination Gloves in the US
  7. Effect of Upadacitinib on Atopic Hand Eczema in Patients With Moderate to Severe Atopic Dermatitis
  8. Allergens in Common Brands of Clobetasol
  9. North American Contact Dermatitis Group Patch Test Results From 2019 to 2020
  10. Early Itch Response With Abrocitinib Is Associated With Later Efficacy Outcomes in Patients With Moderate to Severe Atopic Dermatitis

Most Read This Week

Recently Updated